Erasca Inc. (ERAS) sees its price target raised from $5 to $12 by Guggenheim, following promising clinical data for its lead oncology candidates and updated financial models. The move comes amid a series of positive analyst revisions for the clinical-stage biopharma firm.
Northland Capital has revised its price target for Bitdeer Technologies (BTDR) downward to $25, citing a more conservative valuation approach following the company's latest operational update. The firm, however, reaffirmed its Outperform rating, signaling continued confidence in the blockchain and high-performance computing firm's long-term strategy.
The White House has confirmed the launch of a major strategic initiative to stockpile rare earth elements, aiming to reduce American dependence on China for the critical minerals used in defense tech and consumer electronics.
Analysts at Stifel have raised their price target for Nurix Therapeutics (NRIX) to $35, maintaining a Buy rating ahead of anticipated 2026 clinical milestones for its lead asset, bexobrutinib. The move comes as Wells Fargo also adjusted its target, highlighting divergent near-term views but shared long-term optimism for the biotech firm.
Emily Beutner, a 22-year-old Loyola Marymount University student and daughter of mayoral hopeful Austin Beutner, has died following a medical emergency near a Palmdale highway. The death is under investigation by homicide detectives.
The consumer goods giant reported stronger-than-expected Q4 results, citing growth across key metrics despite inflationary pressures. As it rolls out its ambitious 2030 growth plan, management warns of a volatile global operating environment in the year ahead.
Aris Mining (TSX:ARIS) has undertaken a significant corporate restructuring, reinstating founder Neil Woodyer as both Chairman and CEO while outlining elevated production goals for 2026. The move, aimed at streamlining operations, places the company's ambitious Marmato expansion and near-term execution squarely under Woodyer's renewed command.
Following a price target adjustment by Leerink Partners, Kura Oncology (KURA) is drawing investor focus to its 2026 clinical milestones and commercial strategy for its newly launched AML drug, ziftomenib.
Satellite communications provider Viasat (VSAT) saw its shares hit a new 52-week peak of $46.49, capping a remarkable 12-month rally. The surge follows a significant price target upgrade from Morgan Stanley and the successful launch of a key global network for government clients.
Reed Jobs, son of the late Apple co-founder Steve Jobs, has secured over $200 million for Yosemite, a venture fund dedicated to pioneering cancer treatments. Backed by major institutions, the fund seeks to transform cancer from a fatal diagnosis to a chronic, manageable disease within a generation.
Shares in Alligator Energy (ASX:AGE) jumped sharply after the company announced key progress at its Samphire uranium project in South Australia, including the launch of a field recovery trial and advancing mining lease approvals, setting the stage for a bankable feasibility study targeted for early 2027.
A new mandatory scheme requires all UK fuel stations to report price changes within 30 minutes, with data fed to comparison apps. The government-backed initiative aims to boost competition and save households an estimated £40 annually.
Extreme Networks reports Q2 revenue of $317.9M and net income of $7.9M, while launching an AI-integrated partner initiative aimed at streamlining sales and driving higher-margin software revenue.
Deutsche Bank reported meeting its key 2025 financial objectives, including a 10.3% return on tangible equity, and outlined a path to boost profitability above 13% by 2028. The update, delivered during a fixed income call, highlighted revenue growth, cost discipline, and a strengthened balance sheet, even as management signaled caution on parts of the commercial real estate market.
B2Gold's shares have surged over 117% in the past year, fueled by strong operational performance and renewed investor confidence in gold. As the stock consolidates recent gains, analysts debate whether its current valuation fully prices in future growth from key projects like Fekola and Goose.
Citi has updated its model for GlobalFoundries, lifting the price target to $42 and extending its valuation horizon to 2027. The move follows the chipmaker's strategic acquisition of Synopsys' ARC Processor IP business, aimed at accelerating its physical AI roadmap.
Millions of Social Security beneficiaries will see their February payments arrive on schedule, with amounts reflecting this year's cost-of-living adjustment. Here is the complete calendar and key details.
French biopharma firm Inventiva (ENXTPA:IVA) has delivered a stunning 126% total return to shareholders over the past year, sharply contrasting with losses over a three-year horizon. As the stock experiences short-term pullbacks, analysts debate whether its current €5.23 price reflects future promise or present hype, with a key drug candidate hanging in the balance.
Vodafone Group's shares have soared over 62% in the past year, dramatically outperforming the broader market. As the stock consolidates near £1.06, investors are grappling with a critical question: does the rally still have legs, or has the value opportunity evaporated? A deep dive into cash flow and valuation metrics suggests the story may be more complex than the headline numbers imply.
Newly launched oral weight-loss drug Wegovy from Novo Nordisk recorded more than 26,000 U.S. prescriptions in its second full week, signaling robust early demand as competition with Eli Lilly intensifies.
